Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
NCT06433635
Recruiting
This is a sequential multiple assignment randomized trial for adults (ages \> 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Bipolar I Disorder, Depression
Register for Updates
Platform Clinical Study for Conquering Scleroderma
NCT06195072
Recruiting
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Register for Updates
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928
Recruiting
The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.
Gender:
ALL
Ages:
All
Trial Updated:
05/21/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Register for Updates
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
NCT06192576
Recruiting
US, multicenter, cohort, open label observational study with primary data collection. Ancillary protocol-specified procedures to address the study objectives (eg, assessment of ADA) may be considered outside the standard of care for acid sphingomyelinase deficiency (ASMD), but the study methodology remains non-interventional, as the additional collection of data from participants will not dictate treatment. The total overall study duration will be 5 years. The follow-up period will be a minimum... Read More
Gender:
ALL
Ages:
2 years and below
Trial Updated:
05/21/2025
Locations: Pulse InfoFrame US Inc., Philadelphia, Pennsylvania
Conditions: Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
Register for Updates
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Primary Biliary Cholangitis
Register for Updates
Optimizing a Mobile Health Platform for Sleep Promotion and Obesity Prevention in Children
NCT05703347
Recruiting
The overall objective of this application is to develop a mobile health platform for the pediatric care setting to promote longer sleep duration for childhood obesity prevention.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
05/21/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Insufficient Sleep, Obesity
Register for Updates
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
NCT05233618
Recruiting
In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive up to about 9 cycles of treatment with Tag and have a bone marrow biopsy after cycle 4 and about 1 year after HCT.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Register for Updates
Matching Perfusion and Metabolic Activity in HFpEF
NCT04913805
Recruiting
This study will test whether pharmacologic agents that increase perfusion \[Potassium Nitrate (KNO3)\], with and without additional supplements that may improve mitochondrial function \[Propionyl-L-Carnitine (PLC) and Nicotinamide Riboside (NR)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
NCT02984761
Recruiting
Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania
Conditions: Lung Neoplasm
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/21/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Langerhans Cell Histiocytosis
Register for Updates
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
NCT06541002
Recruiting
This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Sexual Dysfunction, Stem Cell Transplant Complications, Bone Marrow Transplant Complications
Register for Updates
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
NCT06376162
Recruiting
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
05/20/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
Register for Updates